None listed
Conditions
Interventions
Case group:None
Sponsors
Huashan Hospital Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Healthy Chinese subjects aged from 18 to 45, male and female; 2. BMI range 19~26 kg/m2 (included), and body weight = 50 kg; 3. Good health; 4. Take effective contraceptive measures during the study period; 5. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Have a history of allergy to polymyxin drugs; 2. Have a history of allergic disease, kidney disease, nervous system or heart disease/family history; 3. People with acute and chronic infection, or any infectious diseases within 4 weeks before administration; 4. Those who are smoking within 3 months before screening and cannot be banned from smoking in the test, or drink excessively or contain caffeine within 6 months; 5. Major surgery was performed within 3 months before the first dose, or blood donation or blood loss exceeded about 400ml; 6. Use the drug 2 weeks before the first dose or within the expected 5 half-life of the drug; 7. Any vaccine has been vaccinated within 1 month before screening, and there is a vaccination plan during the study; 8. Participated in any intervention clinical study within 3 months before screening; 9. Within 90 days after the last dose, the female subjects or male subjects' female partners have a pregnancy plan, and the male subjects have a sperm donation plan; 10. Female subjects are pregnant or nursing; 11. ECG, vital signs, transaminase and serum total IgE were abnormal during screening period, with eGFR<90 ml/min; 12. HIV-Ab, HBs-Ag, HCV-Ab, TPPA test; 13. Positive results of urine drug screening/alcohol screening/nicotine test; 14. There is no suitable vein for puncture or blood sample collection cannot be tolerated; 15. Do not abide by alcohol, smoking cessation and other dietary restrictions during hospitalization.
Contacts
Public ContactKevin Li
Everest Medicines (China) CO., LTD
Outcome results
None listed